DE69433560D1 - Valproinsäure kovalent gebunden an einem lysophospholipid - Google Patents
Valproinsäure kovalent gebunden an einem lysophospholipidInfo
- Publication number
- DE69433560D1 DE69433560D1 DE69433560T DE69433560T DE69433560D1 DE 69433560 D1 DE69433560 D1 DE 69433560D1 DE 69433560 T DE69433560 T DE 69433560T DE 69433560 T DE69433560 T DE 69433560T DE 69433560 D1 DE69433560 D1 DE 69433560D1
- Authority
- DE
- Germany
- Prior art keywords
- activity
- intracellular enzyme
- glycerophosphoryl
- choline
- lysophospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 4
- 230000003834 intracellular effect Effects 0.000 abstract 4
- 108090000790 Enzymes Proteins 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 3
- 239000008777 Glycerylphosphorylcholine Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 abstract 1
- 108090000371 Esterases Proteins 0.000 abstract 1
- 108010064785 Phospholipases Proteins 0.000 abstract 1
- 102000015439 Phospholipases Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000010504 bond cleavage reaction Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL10524493A IL105244A (en) | 1993-03-31 | 1993-03-31 | Prodrugs with enhanced penetration into cells |
| IL10524493 | 1993-03-31 | ||
| PCT/GB1994/000669 WO1994022483A2 (en) | 1993-03-31 | 1994-03-30 | Prodrugs with enhanced penetration into cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69433560D1 true DE69433560D1 (de) | 2004-03-25 |
| DE69433560T2 DE69433560T2 (de) | 2004-12-16 |
Family
ID=11064681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69433560T Expired - Lifetime DE69433560T2 (de) | 1993-03-31 | 1994-03-30 | Valproinsäure kovalent gebunden an einem lysophospholipid |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5985854A (de) |
| EP (1) | EP0691852B1 (de) |
| JP (1) | JP3900533B2 (de) |
| KR (1) | KR100400075B1 (de) |
| AT (1) | ATE259661T1 (de) |
| AU (1) | AU682029B2 (de) |
| CA (1) | CA2159610C (de) |
| DE (1) | DE69433560T2 (de) |
| HU (1) | HU221678B1 (de) |
| IL (1) | IL105244A (de) |
| NZ (1) | NZ263208A (de) |
| SG (1) | SG81890A1 (de) |
| WO (1) | WO1994022483A2 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| DE69535758D1 (de) * | 1994-08-29 | 2008-07-03 | Univ Wake Forest | Lipid-analoge zur behandlung von viralen infektionen |
| US7135584B2 (en) * | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US6313106B1 (en) * | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| AU6485496A (en) * | 1995-07-14 | 1997-02-18 | Glycotech Corp. | Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor |
| US6350780B1 (en) * | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| WO1998035701A1 (en) | 1997-02-11 | 1998-08-20 | Theramark Limited | Drug targeting |
| WO1998041213A1 (en) * | 1997-03-19 | 1998-09-24 | Lxr Biotechnology Inc. | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| DE69840216D1 (de) | 1997-08-08 | 2008-12-24 | Celmed Oncology Usa Inc | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden |
| EP1240922B1 (de) * | 1997-08-08 | 2008-11-12 | Celmed Oncology (USA), Inc. | Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden |
| TWI244924B (en) * | 1998-01-23 | 2005-12-11 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
| IL147749A0 (en) * | 1999-07-22 | 2002-08-14 | Newbiotics Inc | Methods for treating therapy-resistant tumors |
| US6683061B1 (en) * | 1999-07-22 | 2004-01-27 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| US6670341B1 (en) | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| CZ20022507A3 (cs) * | 2000-01-20 | 2003-01-15 | Omegatech, Inc. | Způsob chování králíků |
| AU2001257490A1 (en) * | 2000-05-02 | 2001-11-12 | Newbiotics, Inc. | Improved beta-lactam antibiotics |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| EP1359921A4 (de) | 2001-01-19 | 2006-09-06 | Newbiotics Inc | Verfahren zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen |
| US8552054B2 (en) | 2001-03-23 | 2013-10-08 | Luitpold Pharmaceuticals, Inc. | Fatty amine drug conjugates |
| EP1423107B1 (de) | 2001-03-23 | 2012-05-09 | Luitpold Pharmaceuticals, Inc. | Fettalkohol-arzneimittel-konjugate |
| AU2003211052A1 (en) | 2002-02-11 | 2003-09-04 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| US20050187191A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
| USD692565S1 (en) * | 2010-06-03 | 2013-10-29 | Smith & Nephew, Inc. | Organ protection layer |
| CA140188S (en) | 2010-10-15 | 2011-11-07 | Smith & Nephew | Medical dressing |
| CA140189S (en) | 2010-10-15 | 2011-11-07 | Smith & Nephew | Medical dressing |
| WO2014117176A1 (en) * | 2013-01-28 | 2014-07-31 | Lopez Hector L | Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor |
| CN108659038B (zh) * | 2017-03-31 | 2022-01-11 | 江苏恩华药业股份有限公司 | 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法 |
| CN110407867A (zh) * | 2018-04-28 | 2019-11-05 | 江苏恩华药业股份有限公司 | 丙戊酸磷脂衍生物的新晶型及其制备方法 |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR244F (de) * | 1900-01-01 | |||
| DE3067662D1 (en) * | 1980-01-16 | 1984-06-07 | Lacer Sa | New 2-halo-pyridines, their production and pharmaceutical compositions |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| IT1201151B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| WO1989005358A1 (en) * | 1987-11-30 | 1989-06-15 | University Of Iowa Research Foundation | Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
| DE3801587A1 (de) * | 1988-01-21 | 1989-08-03 | Hoechst Ag | Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
| ES2055907T3 (es) * | 1989-03-07 | 1994-09-01 | Genentech Inc | Conjugados covalentes de lipidos y oligonucleotidos. |
| JPH03133987A (ja) * | 1989-10-18 | 1991-06-07 | Kowa Yakuhin Kogyo Kk | ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法 |
| JPH03275625A (ja) * | 1990-03-23 | 1991-12-06 | Nippon Oil & Fats Co Ltd | 制癌剤およびその製造法 |
| AU7872491A (en) * | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| CH679856A5 (de) * | 1990-07-04 | 1992-04-30 | Lonza Ag | |
| US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| WO1992017185A1 (en) * | 1991-03-29 | 1992-10-15 | University Of Florida | Targeted drug delivery via mixed phosphate derivatives |
| CA2112803A1 (en) * | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Antiviral liponucleosides: treatment of hepatitis b |
| US6015834A (en) * | 1992-10-20 | 2000-01-18 | Toronto Neuroprotection Group | In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer |
-
1993
- 1993-03-31 IL IL10524493A patent/IL105244A/xx not_active IP Right Cessation
-
1994
- 1994-03-30 EP EP94911239A patent/EP0691852B1/de not_active Expired - Lifetime
- 1994-03-30 AU AU63808/94A patent/AU682029B2/en not_active Ceased
- 1994-03-30 AT AT94911239T patent/ATE259661T1/de not_active IP Right Cessation
- 1994-03-30 US US08/481,243 patent/US5985854A/en not_active Expired - Lifetime
- 1994-03-30 HU HU9502866A patent/HU221678B1/hu not_active IP Right Cessation
- 1994-03-30 JP JP52182794A patent/JP3900533B2/ja not_active Expired - Fee Related
- 1994-03-30 NZ NZ263208A patent/NZ263208A/en not_active IP Right Cessation
- 1994-03-30 WO PCT/GB1994/000669 patent/WO1994022483A2/en active IP Right Grant
- 1994-03-30 SG SG9607743A patent/SG81890A1/en unknown
- 1994-03-30 KR KR1019950704313A patent/KR100400075B1/ko not_active IP Right Cessation
- 1994-03-30 CA CA002159610A patent/CA2159610C/en not_active Expired - Fee Related
- 1994-03-30 DE DE69433560T patent/DE69433560T2/de not_active Expired - Lifetime
-
1999
- 1999-03-16 US US09/270,392 patent/US6136796A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU6380894A (en) | 1994-10-24 |
| WO1994022483A2 (en) | 1994-10-13 |
| HUT73669A (en) | 1996-09-30 |
| IL105244A0 (en) | 1993-07-08 |
| ATE259661T1 (de) | 2004-03-15 |
| HU221678B1 (hu) | 2002-12-28 |
| AU682029B2 (en) | 1997-09-18 |
| NZ263208A (en) | 1997-06-24 |
| JPH08508295A (ja) | 1996-09-03 |
| SG81890A1 (en) | 2001-07-24 |
| CA2159610C (en) | 2008-05-20 |
| US6136796A (en) | 2000-10-24 |
| US5985854A (en) | 1999-11-16 |
| IL105244A (en) | 2003-07-31 |
| KR100400075B1 (ko) | 2004-02-25 |
| WO1994022483A3 (en) | 1994-12-22 |
| JP3900533B2 (ja) | 2007-04-04 |
| DE69433560T2 (de) | 2004-12-16 |
| EP0691852B1 (de) | 2004-02-18 |
| CA2159610A1 (en) | 1994-10-01 |
| HU9502866D0 (en) | 1995-11-28 |
| EP0691852A1 (de) | 1996-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69433560D1 (de) | Valproinsäure kovalent gebunden an einem lysophospholipid | |
| NO20034782D0 (no) | Farmasöytisk aktive uridinestere | |
| RS20090086A (en) | Nucleoside analogs with carobxamidine modified monocyclic base | |
| BG104177A (en) | Amlodipin- and atorvastatin-containing therapeutical combinations | |
| NO955352L (no) | Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse | |
| FI953515A (fi) | Fluoksetiinin farmaseuttiset formulaatiot | |
| EP1127579A3 (de) | Verfahren zur Erhöhen der Bioverfügbarkeit oraler Arzneimittel | |
| CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
| ATE374602T1 (de) | Orale kapselformulierung mit verbesserter physikalischer stabilität | |
| RU2000106434A (ru) | N-алканоилфенилаланиновые производные | |
| EP1586558A3 (de) | Bis-sulfonamid-hydroxyethylamino-Derivate als Inhibitoren retroviraler Proteasen | |
| TR200000481T2 (tr) | N-Alkonoilfenilalenin türevleri. | |
| CA2294812A1 (fr) | Composition pharmaceutique solide contenant des derives de benzofuranne | |
| BR0015567A (pt) | Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos | |
| LU90856I2 (fr) | Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables | |
| NO180490C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 2,6-dialkyl-4-silylfenoler | |
| DK0867179T3 (da) | Sammensætning af L-DOPA-estere | |
| TR200202467T2 (tr) | Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formulasyonlar | |
| BR9811937A (pt) | Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados | |
| EP1090635A3 (de) | Verwendung von Ferulasäure zur Behandlung von Bluthochdruck | |
| SE9403160D0 (sv) | Method and means for prevention and treatment of secondary cataract | |
| HUP0004616A2 (hu) | Tetrahidrofurán-származék hidroxi-észtere mint gombaellenes szer prodrogja | |
| FR2715849B1 (fr) | Forme d'administration solide à délitescence rapide d'un principe actif. | |
| DE60040856D1 (de) | Lactalbumin zur kurativen Behandlung von Magengeschwüren | |
| ES2187963T3 (es) | Sales farmaceuticamente aceptables de 3-sulfato de 3-hidroxi-estr-5(10)-en 17-ona activas con estrogenos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: D-PHARM, LTD., REHOVOT, IL |
|
| 8364 | No opposition during term of opposition |